Talib Dosani, MD
Assistant ProfessorCards
About
Research
Publications
2025
Optimizing skeletal health: An analysis of bone-modifying agent prescription patterns and incidence of skeletal-related events in multiple myeloma
Huang A, Sequeira N, Zhang A, de Matos U, Gorshein E, Dosani T, Vankina R, Ali S, Neparidze N, Kumar S. Optimizing skeletal health: An analysis of bone-modifying agent prescription patterns and incidence of skeletal-related events in multiple myeloma. Blood 2025, 146: 4567. DOI: 10.1182/blood-2025-4567.Peer-Reviewed Original ResearchSkeletal-related eventsBone-modifying agentsInternational Myeloma Working GroupInternational Myeloma Working Group guidelinesIncidence of skeletal-related eventsBone-modifying agent administrationBone-modifying agent treatmentMultiple myelomaRadiation to boneRelapsed/refractory MM patientsAcademic cancer centerDiagnosis of MMProportion of patientsYears of followGuideline adherenceDental screeningMM patientsDental clearanceMedian ageFirst dosePathological fracturesSignificant morbidityNewly-diagnosedPrescribing practicesRetrospective study
2024
Outcomes Following Implementation of an Electronic Model for Perioperative Hematologic Consultation
Su D, Rehman S, Wang K, Deng Y, Rose M, Dosani T, Kunstman J. Outcomes Following Implementation of an Electronic Model for Perioperative Hematologic Consultation. Journal Of Surgical Research 2024, 301: 10-17. PMID: 38905768, DOI: 10.1016/j.jss.2024.04.033.Peer-Reviewed Original ResearchHematology consultationSingle-center retrospective studyClavien-Dindo classificationVA Connecticut Healthcare SystemAssess operative outcomesTime to resolutionPrimary outcome measureE-consultationOperative morbidityPostoperative transfusionHematologic complicationsSurgical outcomesNo significant differenceRetrospective studyProcedural dataOperative outcomesProcedural outcomesStudy cohortPatient characteristicsConsult volumeSecondary outcomesHematologic issuesAssociated with changesReferral patternsSurgery
2023
Supportive Care for Patients With Myelodysplastic Syndromes
Stempel J, Podoltsev N, Dosani T. Supportive Care for Patients With Myelodysplastic Syndromes. The Cancer Journal 2023, 29: 168-178. PMID: 37195773, DOI: 10.1097/ppo.0000000000000661.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMyelodysplastic syndromeMyeloid leukemiaLow-risk diseaseTreatment-related complicationsSupportive care interventionsSupportive care measuresAcute myeloid leukemiaBone marrow disordersAntimicrobial prophylaxisFrequent complicationProgressive cytopeniasSupportive careTransfusion supportHigh-risk counterpartsBetter prognosisPalliative careRoutine immunizationCare measuresCare interventionsIneffective hematopoiesisIron overloadCommon causeMarrow disordersSyndrome populationPatients
2022
A Multidisciplinary Quality Improvement Project to Improve Appropriate Inherited Thrombophilia Testing at VA Connecticut
Xiang J, Dosani T, Hauser R, Cosentino D, Merchant N, Rose M. A Multidisciplinary Quality Improvement Project to Improve Appropriate Inherited Thrombophilia Testing at VA Connecticut. Blood 2022, 140: 7864-7865. DOI: 10.1182/blood-2022-168044.Peer-Reviewed Original Research
2021
Impact of Hematology Electronic Consultations on Utilization of Referrals and Patient Outcomes in an Integrated Health Care System
Dosani T, Xiang J, Wang K, Deng Y, Connell NT, Connery D, Levin F, Roy A, Wadia RJ, Wong EY, Rose MG. Impact of Hematology Electronic Consultations on Utilization of Referrals and Patient Outcomes in an Integrated Health Care System. JCO Oncology Practice 2021, 18: e564-e573. PMID: 34914541, DOI: 10.1200/op.21.00420.Peer-Reviewed Original ResearchConceptsE-consultsHealth care systemPatient outcomesElectronic consultationFTF visitsCare systemIntegrated health care systemRetrospective cohort studyType of consultHematology consultUnique cliniciansPeriprocedural managementCohort studyLaboratory abnormalitiesHematology serviceHematologic malignanciesConsultsConsult volumePatientsMalignancyCliniciansHematologyElectronic modalitiesVisitsOutcomesUse of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center
Dosani T, Poteraj A, Parker T, Bar N, Browning S, Gorshein E, Anderson T, Insogna K, Neparidze N. Use of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center. Blood 2021, 138: 4756. DOI: 10.1182/blood-2021-147466.Peer-Reviewed Original ResearchBone-modifying agentsUse of denosumabYale Cancer CenterZoledronic acidMultiple myelomaMM patientsCancer CenterMedian numberPhysician preferenceCommon reasonClinical practiceNew fracturesNuclear factor kappa-B ligandStudy periodApproval of denosumabEfficacy of denosumabIncidence of SREsMain treatment centreSmilow Cancer HospitalSuppress bone turnoverPatient's renal functionBone resorption markersCohort of patientsGlomerular filtration rateDate of diagnosis
2019
Impact of lenalidomide on collected hematopoietic myeloid and erythroid progenitors: peripheral stem cell collection may not be affected
Dosani T, Covut F, Pinto R, Kim BG, Ali N, Beck R, Maitta R, Downes K, Fox R, Reese J, de Lima M, Malek E. Impact of lenalidomide on collected hematopoietic myeloid and erythroid progenitors: peripheral stem cell collection may not be affected. Leukemia & Lymphoma 2019, 60: 2199-2206. PMID: 30845862, DOI: 10.1080/10428194.2019.1573367.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAutograftsBenzylaminesChemotherapy, AdjuvantCyclamsFemaleHematopoietic Stem Cell MobilizationHeterocyclic CompoundsHumansInduction ChemotherapyLenalidomideLeukapheresisMaleMiddle AgedMultiple MyelomaNeoadjuvant TherapyPeripheral Blood Stem Cell TransplantationRegression AnalysisRetrospective StudiesTransplantation, AutologousTreatment OutcomeConceptsImpact of lenalidomideLens exposureClinical implicationsPeripheral stem cell collectionAutologous stem cell transplantationTransplant-eligible patientsStem cell transplantationStem cell collectionSignificant clinical implicationsErythroid progenitorsHematopoietic myeloidInduction therapyLens usePBSC graftsCell transplantationMultiple myelomaPBSC collectionPlerixafor useLenalidomidePatientsCell collectionGraftMobilization agentsHematopoietic progenitorsExposure
2017
Host-related immunodeficiency in the development of multiple myeloma
Dosani T, Mailankody S, Korde N, Manasanch E, Bhutani M, Tageja N, Roschewski M, Kwok M, Kazandjian D, Costello R, Burton D, Zhang Y, Liewehr D, Steinberg SM, Maric I, Landgren O. Host-related immunodeficiency in the development of multiple myeloma. Leukemia & Lymphoma 2017, 59: 1127-1132. PMID: 28792255, PMCID: PMC6750254, DOI: 10.1080/10428194.2017.1361026.Peer-Reviewed Original ResearchConceptsMultiple myelomaLymphocyte subsetsCD57- subsetImmune biomarkersDevelopment of MMMyeloma precursor diseaseNK cell proportionNovel immune biomarkersProgression of SMMMultiparametric flow cytometrySMM patientsImmune changesImmune patternsClinical guidancePrecursor diseaseCell proportionFlow cytometryMGUSPotential markerImmunodeficiencySequential changesMyelomaPatientsPrecursor conditionsProgressionSignificance of the absolute lymphocyte/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma
Dosani T, Covut F, Beck R, Driscoll J, de Lima M, Malek E. Significance of the absolute lymphocyte/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma. Blood Cancer Journal 2017, 7: e579-e579. PMID: 28665418, PMCID: PMC5520407, DOI: 10.1038/bcj.2017.60.Peer-Reviewed Original Research194 Impact of Lenalidomide on Hematopoietic Myeloid and Erythroid Progenitors: Peripheral Stem Cell Collection May Not be Affected
Covut F, Pinto R, Dosani T, Friedman J, Driscoll J, Downes K, Maitta R, de Lima M, Malek E, Jurdi N. 194 Impact of Lenalidomide on Hematopoietic Myeloid and Erythroid Progenitors: Peripheral Stem Cell Collection May Not be Affected. Transplantation And Cellular Therapy 2017, 23: s190-s191. DOI: 10.1016/j.bbmt.2016.12.301.Peer-Reviewed Original Research